Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.
Rajawat
Yadavendra S
YS
Section of Cardiac Electrophysiology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Patel
Vickas V
VV
Gerstenfeld
Edward P
EP
Nayak
Hemal
H
Marchlinski
Francis E
FE
D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001919:Bradycardia / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D017147:Defibrillators, Implantable / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D006827:Hydantoins; D048289:Imidazolidines / Q000009:adverse effects / Q000627:therapeutic use; D010138:Pacemaker, Artificial; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D013015:Sotalol / Q000009:adverse effects / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000628:therapy*; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D006827:Hydantoins; D048289:Imidazolidines; D010879:Piperazines; C086123:azimilide; D013015:Sotalol; D000638:Amiodarone